ReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call Transcript

Aug. 15, 2022 8:17 PM ETReShape Lifesciences Inc. (RSLS)
SA Transcripts profile picture
SA Transcripts
132.62K Followers

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

Michael Miller - Rx Communications, Investor Relations

Paul Hickey - President and Chief Executive Officer

Tom Stankovich - Chief Financial Officer

Conference Call Participants

Anthony Vendetti - Maxim Group

Operator

Good afternoon. Thank you for joining the ReShape Lifesciences Second Quarter 2022 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.

Michael Miller

Good afternoon, and thank you for joining the ReShape Lifesciences second quarter 2022 earnings call. I'm pleased to be joined by Paul Hickey, the newly appointed President and Chief Executive Officer of ReShape Lifesciences; and Tom Stankovich, Chief Financial Officer. Paul will open the call, after which Tom will provide an overview and update on the company's activities and review the financial results for the quarter. He will then turn the call back over to Paul for some closing remarks, after which, we will open up the call to a question-and-answer session.

As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website including the Investor Information section of the website, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission including those factors identified as Risk Factors in the company's most recent annual report on Form 10-K. As an additional reminder, ReShape stock is listed on NASDAQ, trading under the symbol RSLS.

I will now turn the call over to Paul Hickey, President and CEO of ReShape Lifesciences. Paul?

Paul Hickey

Thanks, Michael. Good afternoon, everyone, and thank you for joining us today. I am very excited to be joining ReShape Lifesciences, and I look forward to leading the company during such an exciting juncture. We are working towards our goal of becoming the global leader in physician-led weight loss and metabolic health solutions with a comprehensive integrated slate of products and services, including our flagship Lap-Band Program.

I'm enthusiastic about the demand generated by a multi-tier direct-to-consumer marketing campaign thus far, which continues to be successful and driving patient engagement and filling surgeons pipelines for Lap-Band procedures evidenced by the 19% increase in sequential revenues achieved in the second quarter.

In the second half of the year, we expect a positive trend in sales, as bariatric surgeons regain the ability to proceed with Lap-Band procedures, which were severely restricted in the early years due to the continued COVID-19 pandemic and as patients and providers continue to navigate the typical 6-month mandatory waiting period required by insurers for bariatric or weight loss procedures, including the anatomy sparing Lap-Band.

Our confidence in this growth is strengthened by the success of our multi-tiered direct-to-consumer marketing campaign in helping practices work through patient backlogs, thereby allowing more new patients to pursue this process and further increasing the sales of the Lap-Band and our suite of weight loss in metabolic health solutions.

The prospects for Reshape are a significant reason that I chose to join the company. In addition, my experience as Senior Vice President of Marketing and reimbursement at EnteroMedics, the predecessor company to ReShape gave me invaluable insights into the company's potential to help alleviate the obesity epidemic I am thrilled about the enormous market opportunity ahead of us.

The well-documented obesity epidemic rages on with 2.5 billion people or more than 30% of global population considered overweight or obese. This number is expected to grow to 50% by the year 2030. As a result, the overall bariatric surgical device market is projected to be a $2.8 billion market worldwide by 2025. The U.S. market alone is estimated to grow to $1.8 billion in this time frame.

Additionally, with 50% of the adults in the U.S. trying to lose weight every year, ReShape is positioned to be a leader in addressing the significant effects of the serious health issue. The anatomy sparing Lap-Band is the only FDA-approved laparoscopic weight loss device commercially available in the U.S. with the safest profile of weight-loss surgeries and is covered by most insurance plans, including Medicare.

In addition to our FDA-approved Lap-Band Program, we have a robust pipeline of weight loss products and services, which we'll discuss in detail during this call. I look forward to working closely with the entire ReShape team to take advantage of this opportunity to expand the company's growth as we execute on our strategy to become the premier physician-led weight loss in metabolic health solutions company.

I would now like to turn the call over to Tom Stankovich to review the recent highlights and provide a recap of our financial performance. Tom?

Tom Stankovich

Thanks, Paul. And once again, thank you all for joining our webcast this afternoon. We have achieved a multitude of important milestones during the second quarter and current period, strengthening our position as a market leader with our integrated portfolio of proven products and services that manage and treat obesity and associated metabolic diseases.

Our recently announced FDA 510(k) clearance for the disposable gastrointestinal balloon indicator, calibration tube is a significant milestone for the company. We expect this line extension of calibration tubes to be rapidly adopted by surgeons given their ability to help better visualize the anatomy, making it easier to identify potential defects during a broad range of bariatric procedures such as laparoscopic sleeve gastrectomy, gastric bypass and adjustable gastro banding.

We look forward to formally introducing this new important product at the International Federation for surgery of obesity and metabolic disorders, World Congress in Miami later this month and expect to commercial sales to begin in September.

Our partnership with OpenLoop, an expert in full stack virtual care delivery services provides a nationwide physician-led telehealth solution for reshapecare, which vastly extend the reach of our proprietary digital therapeutic weight loss and wellness program. It is important to note, reshapecare is a doctor prescribed and may be covered by insurance for up to 26 visits for reimbursement year, making it an effective and convenient virtual health coaching programs.

In partnership with physicians, the program is differentiated by the current virtual weight loss market through live video-based counseling with doctors and board-certified health coaches, to ensure the most comprehensive and customized care possible, including implementing behavioral change to improve sleep nutrition exercise in stretch levels. reshapecare is appropriate for all weight loss patients, including medical weight loss and pre and postsurgical bariatric patients.

As a result, we are able to tap into the virtual health care delivery space, a market that is expected to reach $95 billion by 2026. Specifically, the rollout of reshapecare and its extension ReShape Marketplace, which includes advanced line of premium supplements allows ReShape to distinguish itself as an incredibly valuable e-commerce platform of health care provider recommended competitively priced weight loss and wellness products for bariatric surgery and medical weight loss patients that support nutrition exercise, sleep and stress.

We remain encouraged by the continued pace of inbound requests from bariatric surgeons for refresher courses on the Lap-Band Program. In fact, this year, dozens of bariatric surgeons have approached us for recertification, which is an acknowledgment of the growing patient demand and established safety and efficacy of the anatomy sparing Lap-Band procedure.

Keep in mind that this is additive to our existing accounts, and we are receiving a steady flow of requests for refresher courses every week. As we previously noted, we would again like to congratulate Vern Vincent, our Global Director for Clinical training, the ASMBS 2022 distinguished Industry Partner Award, who is leading the retraining effort and facilitating the training of the next generation of bariatric surgeons, including for the first time, bariatric fellows. on the benefits of the Lap-Band during the session at the ASMBS annual conference this past June.

As a result of this renewed interest, the Lap-Band from industry groups such as ASMBS, our focus has been on both reengagement of accounts that have historically used the Lap-Band and bringing in new accounts, especially within the underserved major markets.

Doctors are realizing that Lap-Band can be additive to their practices and that is not taking away any business from more aggressive stapling and gastric bypass procedures. We are creating a whole new market for people who don't want those procedures that may be giving up on diets.

We are enthusiastic about this trend and expect a steady stream of practices to request training going forward buoyed by our multi-platform DTC advertising campaign, which continues to drive patient engagement.

The anatomy sparing Lap-Band is unrivaled in the market, and it is adjustable, reversible and well-proven with over 1 million bands having been placed in patients globally in the last 20 years, demonstrating an incomparable safety profile compared to highly aggressive stomach stapling procedures and diets. Adjustability, reversibility and having personal control are all highly desirable aspects for potential patients when making bariatric surgery decisions.

Additionally, the reduced risk of adverse events and nutritional deficiencies, associated with anatomy-altering procedures have also been identified as being of great significance in this decision-making process. The fact that most patients return home the same day as their Lap-Band procedure, which is available in outpatient surgery centers is also a key determining factor in the weight loss procedure decisions.

As a reminder, our multi-tiered DTC marketing campaign has utilized strategically placed national television print and now to a greater extent, targeted digital media in order to market our Lap-Band program with available after care supported to reshapecare.

From the outset of the campaign, we have leveraged the highest viewed television channel and printed publications with the goal of effectively communicating the benefits and differentiated advantages of the Lap-Band, which have been featured in over 15 major magazine publications, including people, good housekeeping, better homes and gardens and over 28 national stations, including Bravo, Lifetime USA and A&E and Hallmark, all of which focus on our target audience.

We continue to improve on these marketing efforts through diligent metric analysis and adaptation while also incorporating co-op marketing partnerships, local digital media and national social media influencer campaign.

We have been successful in creating and building customer engagement, which has led to increased patient demand for the Lap-Band Program, which has then led to the filling of bariatric surgeons pipelines. Today, we can track customer engagement, leads and warm [ph] transfers of qualified patients, to practices with a high level of confidence.

Based on tracking these metrics, we have been able to adapt our DTC marketing campaign to be more effective and more efficient. This will all lead to increased Lap-Band procedures and thus potentially a significant increase in revenues for ReShape Lifesciences over time. The results of this campaign have been overwhelmingly positive so far indicating that our message is clearly resonating with the consumer and professional markets.

In fact, doctors were working hard to catch up from the demand backlog that the marketing campaign created while surgery centers were shut down. The typical 6-month mandatory waiting period imposed by insurers creates a lag between early engagement and actual procedures. This means that after we transfer a warm lead to a doctor from our DTC campaign, insurers will require a patient to go through several steps, which may include behavioral analysis, physical analysis or perhaps trying a medically managed weight loss program one more time to make sure they can't lose weight that way and need surgery.

This represents a lag between the preliminary investment towards our marketing efforts, initial patient engagement and scheduled procedures. As these scheduled procedures are starting to flow, we are really excited what the next few quarters could look like based on the metrics we are tracking from the DTC campaign. We are now just starting to reap the benefits of this strategic outreach, and we are optimistic that revenue will continue to increase through the remainder of '22 and beyond.

Turning to a review of our financial performance. A full discussion of our financials is available in our press release and 10-Q. So I will just take a moment to review key financials for the second quarter ended June 30, 2022.

Our revenue totaled $2.9 million for the 3 months ended June 30, 2022, which represents a contraction of 18.1% versus the same period in 2021. As I explained earlier, the primary reason for this decline is the COVID-19 Omicron variant, which caused a significant number of bariatric centers to close in January, February and into March 2022. As a spread of the Omicron variant began to subside, we were pleased to have experienced a 19% increase in sequential revenues compared to the first quarter.

As I noted in my prior remarks, we expect sales to continue to increase through the remainder of 2022, as we have witnessed continued growth in patient engagement and doctor consultations attributable to our DTC marketing campaign.

We reported gross profit of $1.9 million compared to $2.2 million for the 3 months ended June 30, 2021, Gross profit as a percentage of total revenue for the 3 months ended June 30, 2022, was 65.1%, a solid improvement compared to 61% for the same period in 2021. The gross profit margin increased during the 3 months ended June 30, 2022, primarily due to the company at a higher percentage of domestic sales than in the same period of 2021, which has a higher gross profit margin than international sales.

Sales and marketing expenses for the 3 months ended June 30, 2022, increased to $4.7 million compared to $1.4 million for the same period in 2021. The increase is primarily due to an increase in advertising and marketing costs of $1.8 million after having launched the DTC marketing campaign during the fourth quarter of 2021 and expanding this campaign during the first half of 2022.

There were also increases related to strengthening the commercial organization and increase in consulting and professional fees related to the launching of the digital media platform, as well as other smaller increases such as travel-related expenses as markets began to open up again.

General and administrative expenses for the 3 months ended June 30, 2022, increased to $5.4 million compared to $4.3 million for the same period in 2021. The increase is primarily due to $2 million of legal expenses and increases in stock-based compensation of $1.2 million and an increase in payroll expense as we continue to make strategic organization changes. This was offset by a decline of $2.3 million in consulting and other professional fees that the company has significant related costs during the second quarter of 2021 due to the merger with Obalon.

Research and development expenses were $800,000 for the 3 months ended June 30, 2022, compared to $100,000 for the same period in 2021. The increase is due to an increase related to consulting fees and an increase in payroll expenses, including stock-based compensation.

On a non-GAAP adjusted EBITDA basis, the loss of $7.8 million for the 3 months ended June 30, 2022, compared to a loss of $1.2 million for the same period last year. It is important to note that revenues were delayed due to the mandatory wait period of approximately 6 months for insurance verification purposes, which we previously discussed.

The increased loss is primarily due to the previously mentioned increase in advertising and marketing costs from the DTC marketing campaign, a related increase in payroll expenses due to the expansion of the commercial team, an increase in stock-based compensation and an increase in legal expenses.

Lastly, during the quarter, we continued to strengthen our balance sheet, grossing $2.5 million in proceeds from warrant exercise after having eliminated all debt previously from our balance sheet at the end of last year. We ended the quarter with $11.5 million in cash and cash equivalents, which combined with an increase in revenues for the second half of 2022 and beyond should extend our cash runway well into 2023.

With that, I will now turn the call back over to Paul.

Paul Hickey

Thanks, Tom. Before we open the call for Q&A, I'd like to take a moment to review the status of a few of additional products in our pipeline. As mentioned last quarter, we continue to evaluate the ReShape Vest. We remain in contact with the clinicians and clinical sites regarding the EU clinical trial which was paused due to the lack of access to patients and facilities caused by the COVID-19 pandemic.

Additionally, we continue to explore the manufacturing liability and market opportunity, which would be necessary for the reintroduction of the Obalon Balloon System. The technology is the first and only swallowable gas-filled FDA-approved balloon system introduced into the U.S. weight loss marketplace as a non-surgical minimally invasive products. We'll provide an update once our analysis is completed.

Also of note, with the assistance of a grant from the NIH, we met the necessary endpoints in order to complete the preclinical development of the ReShape diabetes block stem neuromodulation device, a novel investigational device using neuromodulation to adjust insulin production and potentially treat type 2 diabetes. We have submitted an application for a second grant with the NIH and hope hear back in the near future. We remain committed to further evaluating the potential of this product, which is backed by a strong intellectual property portfolio through a non-dilutive funding strategy.

Finally, we will continue to evaluate M&A opportunities that align with our commitment to the physician-led weight loss and metabolic solutions market, specifically those that can enhance our current product portfolio and be accretive to our value.

We are pleased with our recent efforts and achievements and are optimistic that the upward trend in sales we are experiencing will continue through the balance of 2022 and beyond. Through our national direct-to-consumer marketing campaign and other visibility programs, we will continue to maintain focus on marketing and the proven advantages of our FDA-approved insurance reimbursed anatomy sparing Lap-Band Program, along with the rest of our portfolio of physician-led weight loss solutions.

This concludes our prepared remarks. So now we'd like to open the call to your questions. Operator?

Question-and-Answer Session

Thank you. [Operator Instructions] Thank you. And we'll take our first question from Anthony Vendetti from Maxim Group. Your line is open.

Q - Anthony Vendetti

Thank you. Tom, maybe if you could talk a little bit or Paul, if you want to on the recent FDA approval for the deadline extension, how that - for those disposables, how is that going to impact, do you believe the top line and eventually, maybe give a little time frame on when you're going to start to commercialize that. And then have a follow-up call on reshapecare?

Tom Stankovich

Sure. Thanks, Anthony. It's Tom here. Thanks for the question. So yes, the GB launch for us is very important, strategic. It's very, very good news for the company. As you may recall, we were selling - we were selling this in the wrong sizes. We were - now we've got 510(k) approval for the most popular sizes that the bariatric surgeons are using today. So that's just the benefit of what we've been - we have been doing and what we will be doing going forward.

So I expect some nice revenue increases as far as this is concerned as it gets to be rolled out. We plan to have this go commercial in September. We're going to introduce it at the IPSO conference that's upcoming next week in Miami. And we expect it to gain some traction early on.

Again, that is going to be in the more popular tube sizes that the surgeons are using. And we expect a nice bump in revenues, even starting this year and into next year.

Anthony Vendetti

Okay. Great. So commercialization in September and start to contribute to revenues by the end of this year. And then on reshapecare, do you have a number in terms of how many patients have signed up for any feedback so far? I know it's early stages I know you signed an agreement with a company that was going to incorporate reshapecare. So I was wondering what kind of early feedback you have so far?

Tom Stankovich

Early feedback that we've been getting is very good. We are about to really significantly launch reshapecare. So the feedback that we've gotten, we've been working some of the kinks out in the system as far as how the whole process, as we're able to work through coaching some of the patients.

But – so this is also going to become a very mainstream for us in the coming weeks and months. And again, expect to have a revenue balance from - for reshapecare even during - before the end of this year. We're very excited with the whole reshapecare program.

Anthony Vendetti

Okay. Great. And in terms of the Lap-Band itself, you've been putting in towards the end of last year, particularly October, November and into December, some significant dollars into advertising and magazines, and print journals and so forth. Can you just talk about your level of comfort or if you feel like those dollars are giving you the ROI. What I believe is after the initial launch, you fine-tuned it a little bit more. Do you feel comfortable with it - where you're at now? Or do you think you need to continue to fine-tune it for spending more dollars there?

Tom Stankovich

I think great question. But I do think, the easy answer to your question we're 100% happy with the way things have gone as far as the whole DTC advertising campaign. The amount of website traffic that we've had, the amount of leads that we have had, those leads that turn into warm transfers as we like to call them and then ultimately consultations with doctors. We're extremely happy with that. And we had to do that on larger scale initially to effectively launch the whole Lap-Band Program.

We've learned a lot from that. And some of the things we have learned is to - the whole DTC campaign was to where we can tune things up a little bit, where we can tune things down a little bit also. Right now, we're starting to do a lot more in the way of digital marketing and social media to do a lot more in the way of digital marketing and social media marketing and to be honest with you, that's going to be - that's going to cost us significantly less also going forward.

A lot of the expensive advertising that we did on a national basis and TV and national prints, I don't need to go into a whole lot of detail explaining that. That's very expensive to do. But that laid the foundation and I think we needed to do that to get the Lap-Band back out there in the marketplace. Now we can target a little bit, a little bit better, and we're going to do that through more digital marketing and social media.

Paul Hickey

Anthony, this is Paul Hickey First off, I just want to publicly thank Tom for taking the role as Interim CEO in the last few weeks. Much appreciated kept the machine operational and everything running smoothly with all the employees and the great team we have here at ReShape.

I completely agree with the answer he just gave. I just want to emphasize, too, I mean, our ongoing business plan, and I guess the business model is to optimize the dollar spent to drive leads to our physicians. And part of that is as Tom indicated, working with sort of a national splash and then as time moves on, continue to optimize that into different media outlets, as well as watching the shifts from dollars we've spent to also watching our centers dedicated funds to market their practices and drive additional patients into their settings to ultimately treat them with Lap-Bands.

So committed to it. As far as return on investment, it just gets better over time because of us very being diligent about looking at the metrics and making sure that we understand where the dollars are spent and what leads are generated.

One additional tool that the company added prior to my arrival was Salesforce as their CRM tool. It's probably the best in the industry that I've experienced in the past. And I think that's truly going to track metrics by region, by state, by practice, again, making sure that the media outlet, the media channel that we use, whether it's social or national or radio, whatever, will be tracked for how warm the leads are and whether or not the physician and their programs are able to convert to Lap-Band.

Anthony Vendetti

Great. That's helpful color. Thanks, Paul. And I know today is your first day. So welcome aboard.

Paul Hickey

Thank you

Operator

Thank you. This concludes our question-and-answer session. I would like to turn the call back over to Paul Hickey for any closing remarks. Please go ahead.

Paul Hickey

Great. Thank you. Well, I hope you all recognize our enthusiasm and share our excitement further on ahead, given the substantial growth opportunities we have before us. We believe wholeheartedly that the benefits offered by the FDA-approved minimally invasive, safe and effective Lap-Band and the suite of weight loss solutions will continue to attract interest and that we are just beginning to reap the benefits of our proactive direct-to-consumer marketing campaign.

I want to thank our employees, board members, customers, vendors, existing and new shareholders for your continued support of ReShape, as we progress on our mission to become the premier physician led weight loss company. I look forward to the opportunity I have at ReShape and to providing future updates.

Michael Miller

his conference has now, sorry, conference call has now concluded. Thank you for attending today's call. You may now disconnect.

Operator

Thank you. Everyone, have a great day.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.